![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C33H41N3O10S2 |
Molar mass | 703.82 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Brecanavir ( INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV. [1]
In December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation. [2]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C33H41N3O10S2 |
Molar mass | 703.82 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Brecanavir ( INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV. [1]
In December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation. [2]